KOSDAQBiotech & Pharma092040

Amicogen

₩936▲ 0.43%2026-11-18 close
Market Cap
₩66.1B
Turnover
₩200M
Volume
200K
Shares out.
70.7M
PER
—
PBR
0.6×
EPS
-₩184
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Amicogen: Media and CMO Commercialization Is the Test Amid Losses

Disclosed revenue fell to KRW 42 billion in 2025 after a China subsidiary was deconsolidated, and in 2026 quarterly results have swung while securing commercial volume at the Songdo media plant remains the central task.

  1. 1

    Disclosed 2025 revenue was KRW 42 billion, down 75.8% year on year, and the company attributes the main cause to the partial sale of a China subsidiary that left the consolidation scope.

  2. 2

    Operating losses were KRW 7.05 billion in 2024 and KRW 17.1 billion in 2025, two straight loss years, and the 2025 operating margin fell to -40.8%.

  3. 3

    Net loss attributable to controlling shareholders continued for four consecutive years from 2022 to 2025, and after a KRW 19.7 billion profit in Q1 2026, Q2 and Q3 posted losses again.

  4. 4

    The company said media and resin sales totaled about KRW 600 million in 2025 while those units posted losses in the KRW 10 billion range, so commercialization speed is the key variable.

  5. 5

    After a KRW 17.4 billion public share offering in February 2026, borrowings fell from KRW 109.3 billion at end-2024 to KRW 64.7 billion in March 2026.

02

Business structure

Amicogen is a company focused on enzymes and bio-materials, selling antibiotic-synthesis enzymes, specialty pharmaceutical enzymes, collagen-based raw materials, and functional ingredients such as the joint-health material NAG.

The company runs two business divisions, one for enzymes and biopharmaceuticals and one for bioprocessing and CDMO, and its media and resin businesses sit in the latter.

The media business is based on a GMP plant in Songdo, Incheon, and the company said in October 2026 that it had fully launched contract manufacturing of customer-specific media.

The Songdo plant can produce both powder and liquid media, and the company is running media evaluations or related projects with about 30 domestic and overseas firms, including 13 antibody biopharmaceutical companies and 11 cell therapy companies.

Management plans to build three business pillars: commercial custom-composition media CMO, catalog media for research, and joint development of customized media.

Resin operations are handled by its subsidiary Furiogen, and the company said it is undergoing quality verification and sample testing with global large pharma companies.

According to the company, media sales were about KRW 370 million and resin sales about KRW 250 million in 2025, so the new businesses are a very small share of disclosed revenue.

Because media, once qualified in a commercial process, is hard to switch away from, whether evaluations convert into repeat sales will likely decide the business outcome.

On November 6, 2026, the company signed a strategic MOU with China-based cell culture media maker CelluPro, which it disclosed on November 12, and the two sides are discussing contract manufacturing at the Songdo plant.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩10.1B-₩4.7B−46.1%
2025Q4₩10.9B-₩3.9B−35.8%
2026Q1₩12.3B-₩3.2B−25.8%
2026Q2₩13.4B-₩1.3B−9.7%
2026Q3₩11.5B-₩2.6B−22.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩144.3B-₩4.9B-₩47.2B−3.4%−35.8%153.1%
2023₩159.9B₩2.1B-₩23.3B1.3%−13.2%113.3%
2024₩173.6B-₩7.1B-₩52.8B−4.1%−43.1%139.0%
2025₩42B-₩17.1B-₩30B−40.8%−31.7%141.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Disclosed revenue rose from KRW 144.3 billion in 2022 to KRW 159.9 billion in 2023 (up 10.8% year on year) and KRW 173.6 billion in 2024 (up 8.6%), then fell to KRW 42 billion in 2025 (down 75.8%). Among 2022 to 2025, 2024 was the largest year and 2025 the smallest.

The company attributes the 2025 decline to the partial sale of its China subsidiary (48.78% stake), which was reclassified as an associate and left the consolidation scope at the end of December 2024.

Operating results moved from an operating loss of KRW 4.9 billion in 2022 to an operating profit of KRW 2.06 billion in 2023 (a turn to profit), then to an operating loss of KRW 7.05 billion in 2024 (a turn to loss) and KRW 17.1 billion in 2025 (losses widened), making 2024 and 2025 two consecutive loss years.

The 2025 operating margin of -40.8% reflects losses widening while the revenue base shrank.

In 2023 the company was profitable at the operating level yet still posted a net loss attributable to controlling shareholders of KRW 23.3 billion; press reports tie this to borrowings and convertible bonds raised for new businesses that became a financial burden.

Net loss attributable to controlling shareholders was KRW 47.2 billion in 2022, KRW 23.3 billion in 2023, KRW 52.8 billion in 2024 and KRW 30 billion in 2025, four consecutive loss years, while the 2025 net loss including non-controlling interests was KRW 30.4 billion.

Operating cash flow moved from KRW 8.64 billion positive in 2023 to negative KRW 13.3 billion in 2024 and negative KRW 24.4 billion in 2025, and the debt-to-equity ratio rose from 113.3% in 2023 to 139.0% in 2024 and 141.9% in 2025.

On a quarterly basis, revenue climbed from KRW 10.1 billion in Q3 2025 to KRW 13.4 billion in Q2 2026 before dropping to KRW 11.5 billion in Q3 2026 (down 13.8% quarter on quarter, up 13.8% year on year).

Operating loss narrowed from KRW 4.68 billion in Q3 2025 to KRW 1.3 billion in Q2 2026 before widening to KRW 2.58 billion in Q3 2026, and the company has posted losses for five consecutive quarters from Q3 2025 to Q3 2026.

The KRW 19.7 billion profit attributable to controlling shareholders in Q1 2026 is far larger than that quarter's operating loss of KRW 3.17 billion, so non-operating items likely played a large role. The combined net loss attributable to controlling shareholders over the last four quarters was KRW 11.4 billion.

05

Industry analysis

In domestic bio production, cell culture media is a material that is hard to switch once it enters a commercial process, so adoption tends to produce recurring demand.

Media is a core input for antibody and antibody-drug conjugate (ADC) development and production, and CelluPro is also pitching joint development of customized media in this area. The reorganization of global supply chains around regions is becoming clearer.

CelluPro is trying to diversify a manufacturing base concentrated in China by adding Korea, and Amicogen is seeking to draw that demand toward its Songdo plant. In antibiotic raw materials, Amicogen's enzymes face the task of moving beyond a China-centered supply structure toward customers in Europe and Japan.

Amid geopolitical tension, efforts to restructure supply chains for essential medicines are also drawing attention to enzyme-based production technology. However, compared with large CDMO peers such as Samsung Biologics and Celltrion, the company's production scale and revenue base are small.

Market share data for media and resin is not backed by disclosed figures here, so the comparison stays qualitative. In functional materials, DCI has been presented in Europe as a material classified as non-novel food, which reduces the burden of new food approval for partners.

06

Outlook

At its April 2026 shareholder meeting, the company set its 2026 media revenue expectation at KRW 10 billion. In October 2026 it said it had completed equipment qualification, validation and quality system setup at the Songdo plant and begun contract manufacturing of customer-specific media.

The November 2026 MOU with CelluPro covers joint R&D, co-branding, mutual sales and contract manufacturing at the Songdo GMP plant, but the scale and supply schedule will be set in later discussions.

On the enzyme side, a European patent for CX, a first-stage enzyme used in next-generation 7-ACA synthesis, has been registered, and examination is under way in India.

The company is running production validation with European and Japanese companies and has set a goal of applying the technology on commercial lines in 2027. On finance, it raised funds through a February 2026 share offering and said it plans to refinance borrowings with safer loans.

Its target was to reach preferred-negotiation status with a strategic investor (SI) by April 2026, and whether that result materializes will need to be confirmed through future disclosures.

For its resin subsidiary Furiogen, the company is considering a listing under the small and medium parts and materials track and said it is considering filing for preliminary review early next year.

In May 2026 the company set a goal of signing export contracts and launching products locally in the second half of the year.

07

Valuation

PER
—
PBR
0.6×
ROE
-10.8%
EPS
-₩184
BPS
₩1,617
Dividend per share
₩0

The price-to-book ratio is below 1x, so the share price sits at a discount to book net assets. Because the last four quarters combined show a net loss attributable to controlling shareholders, earnings-based multiples cannot be calculated, and valuation leans more on asset value.

The dividend yield is below the industry average since no dividend is being paid. Total equity at the end of 2025 was KRW 95.9 billion, down from KRW 123.1 billion at the end of 2024, of which KRW 94.6 billion belongs to controlling shareholders.

The February 2026 share offering substantially increased the number of shares, and in March 2026 the company decided to fully retire a KRW 31.7 billion third convertible bond to remove a dilution factor. A share price below net asset value can be read as reflecting both accumulated losses and debt burden.

Whether asset value holds up depends on whether commercial sales from media and resin can change the loss structure, so valuation is best read alongside business results disclosures.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Media and CMO Commercialization Entry

Contract manufacturing of customer-specific media began at the Songdo plant in October 2026, with about 30 firms in evaluations or related projects. If the company's KRW 10 billion media revenue target for 2026 is achieved, the weight of the new businesses would change meaningfully. The November 2026 MOU with CelluPro was presented as a way to expand into overseas commercial media markets.

Enzyme Patent and Overseas Expansion

A European patent for the CX enzyme used in next-generation 7-ACA synthesis has been registered, extending protection beyond Korea, the United States, China and Japan. The company is running production validation with European and Japanese firms and aims to apply the technology on commercial lines in 2027. Whether this moves the company beyond its China-centered supply structure is the point to confirm next.

Narrowing Losses and Balance Sheet Repair

Operating loss narrowed from KRW 4.68 billion in Q3 2025 to KRW 1.3 billion in Q2 2026, showing a period of quarterly narrowing. Borrowings fell from KRW 109.3 billion at end-2024 to KRW 64.7 billion in March 2026, and the decision to retire the convertible bond in full removed a dilution factor.

A new chairman, Yang Jae-jung, was brought in to lead normalization of management, liquidity and balance sheet repair.

09

Bear factors

Shrinking Revenue Base and Wider Losses

Revenue fell 75.8% to KRW 42 billion in 2025, and operating loss widened to KRW 17.1 billion. The 2025 operating margin was -40.8%. The operating loss widened again to KRW 2.58 billion in Q3 2026 after the prior quarter, and losses have continued for five consecutive quarters.

Debt and Cash Flow Burden

The debt-to-equity ratio was 141.9% in 2025, higher than 113.3% in 2023. Operating cash flow was negative KRW 24.4 billion in 2025. Of the remaining financial-sector debt of KRW 55.6 billion, a figure in the KRW 40 billion range is a development bank loan secured by the Songdo media plant. The February 2026 offering added new shares equal to 26.8% of the prior total, diluting existing holders.

Possible Delay in New Business Commercialization

Media and resin sales totaled about KRW 600 million in 2025, while the losses of those units were in the KRW 10 billion range. The company said passing global customers' quality documentation and sample testing took longer than expected.

The strategic investor timeline was discussed more than once, and the outcome has yet to be confirmed in disclosures.

10

Risk factors

Governance and Investment Raise

After the change in control following the founder's removal, the delay in attracting a strategic investor heightened liquidity concerns. The company said stabilizing its largest shareholder is urgent, but the timing of a firm investment commitment is still undecided.

The longer the delay, the less funding may remain for the media and resin businesses, so SI progress must be confirmed in upcoming disclosures.

Subsidiary Listing and Shareholder Value

The plan to list resin subsidiary Furiogen has raised concern among shareholders over whether they will benefit. The company said it could use the small and medium parts and materials track, but it said giving existing shareholders separate benefits lacks an institutional basis and is hard to pursue first. How the parent and subsidiary listing structure is ultimately arranged will shape shareholder value.

China Supply Chain and Regulatory Environment

Sales and partnerships are tied to China, so geopolitical variables and local regulatory changes could affect operations. Because the sale of the China subsidiary stake changed the consolidation scope in 2025, the scope of China-related impact on results has also shifted.

The CelluPro cooperation is a joint venture with a Chinese partner, so changes in the institutional environment could affect execution speed.

11

What to watch next

  1. End of December 2026

    The next checkpoint is whether the export contracts and local product launches the company targeted for the second half of 2026 are confirmed through disclosures or reports. Whether media evaluation volumes convert into supply contracts is also a point to follow.

  2. End of March 2027 (annual report filing deadline)

    When the 2026 annual report is disclosed, full-year revenue and operating loss will be fixed as regulated report figures. The gap between the company's KRW 10 billion media revenue target for 2026 and actual media and resin sales is the next point to confirm.

  3. Early 2027

    Whether subsidiary Furiogen files for preliminary review under the small and medium parts and materials track is the next point to confirm. The company said it is considering a filing early next year, which is tied to the debate over benefits for existing shareholders.

  4. 2027 (company target timing)

    The next checkpoints are the target timing for applying the CX enzyme on customer commercial lines and the results of production validation with European and Japanese firms. These indicate whether the China-centered structure is shifting toward a broader global customer base.

  5. After November 2026 (timing undecided)

    The next checkpoints are whether a definitive manufacturing agreement with CelluPro is signed and the scale of contract manufacturing volume at the Songdo plant. The specific scale and supply schedule will be set through follow-up discussions.

12

Overall view

Amicogen entered 2026 with disclosed 2025 revenue of KRW 42 billion and an operating loss of KRW 17.1 billion, meaning its revenue base shrank sharply and losses widened.

The main cause of the revenue decline is deconsolidation after the partial sale of a China subsidiary, a change that differs in nature from business contraction.

In 2026, quarterly results have alternated between narrowing and widening losses, with a profit attributable to controlling shareholders in Q1 but net losses again in Q2 and Q3.

Media, CMO and resin are entering commercialization with the Songdo plant running and the CelluPro cooperation, but combined 2025 sales of about KRW 600 million are not yet large enough to change reported results.

On finance, borrowings have fallen, a share offering was completed and a convertible bond was retired, yet the debt-to-equity ratio of 141.9% remains high and the outcome of the strategic investor search still needs confirmation.

The key checkpoint is the 2026 annual report, which will fix media and resin sales and the full-year operating margin.

Strengths include the commercialization entry, the European patent and balance sheet repair, while weaknesses include the shrinking revenue base, funding uncertainty and continued losses in new businesses.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. amicogen.com
  3. amicogen.com
  4. news.nate.com
  5. amicogen.com
  6. fnnews.com
  7. amicogen.com
  8. gnnews.co.kr
  9. amicogen.com
  10. pharm.edaily.co.kr
  11. newspim.com
  12. fnnews.com
  13. m.ekn.kr
  14. job-post.co.kr
  15. mt.co.kr
  16. markets.hankyung.com
  17. en.fnnews.com
  18. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis